Home
overview

SAE Media Group’s 5th Annual Conference
Injectable Drug Delivery
10 - 11 May, 2023 |
-------------------------------------------------------------------------
As Part of Europe’s leading Injectable conference series, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics, new technologies in device design, along with the latest regulatory considerations for optimal drug delivery.

With increasing demand for vaccines, insulin, and many other modern medicines administered via the injectable route, there is significant growth projected in the biologics market, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery.

At this year’s event we will highlight the most recent innovations within the industry, with regard to injectable device design and the formulation challenges of long-lasting, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years.
 

  • Explore the latest trends within the Injectable drug delivery field, with new insights into in-silico modelling
  • Expand on current knowledge of device design, with special considerations for primary and secondary packaging
  • Examine injectable drug formulation strategies, including novel formulation methodologies
  • Learn how to advance the injectable drug delivery landscape through a review of current regulatory compliance
  • Realise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies

 

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
• Autoinjectors
• Wearables
• Device Engineering
• Human Factors
• CMC
• Injectables
• Sterile Manufacturing
• Packaging
• Regulatory Affairs
 

Previous Attendees Include:

Advanz Pharma; AstraZeneca; Bayer AG; Boehringer Ingelheim GmbH; Boehringer Ingelheim Pharma AG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chiesi Ltd; EVEON; Gerresheimer; GlaxoSmithKline; GSK; IPSEN Pharmsciences; Janssen Pharmaceutical Companies; MedinCell; MHRA; Midas Pharma Gmbh; Midatech Pharma; Novartis; Owen Mumford Ltd; PDM solutions; Pfizer; PHC Corporation; Sabic; SI02 Medical Products ; Stevanato Group S.P.A.; Stewart Urquhart consulting Ltd; Sustainable Healthcare Coalition; Team Consulting Limited; Telstar; Teva; TUV SUD Japan Ltd.; Tyndall National Institute; University of Southern Denmark; Vetter Pharma International GmbH; Vetter Pharma-Fertigung GmbH & Co. KG; Victrex Plc; Viridian Therapeutics;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Tiffany McIntire

Tiffany McIntire, Principal Human Factors Engineer, Roche
View Bio

Thomas Wejs Moeller

Thomas Wejs Moeller, Director Global Regulatory Affairs - Device, Novo Nordisk
View Bio

9:50 An update on insights into the EU MDR from a Notified Body Expert Perspecitve

Julia Frese

Julia Frese, Director, TUV SUD Japan Ltd.
View Bio

  • A review of the industry landscape following MDR implementation and key notified body considerations
  • Lessons in the development of strategic partnerships between the injectable drug industry and the relevant Notified Bodies
  • Assessing the most recent challenges associated with working alongside the EU MDR and ways to overcome them
  • Exploring future directions for the industry, what additional guidance is required for the injectable regulatory landscape
  • 9:50 Streamlining injectable product development through correct CMC practices and regulatory governance

    Louise Place

    Louise Place, Director, Devices Global CMC Regulatory Affairs, GSK
    View Bio

  • Key considerations for injectable drug product strategies from pre-NME to post-NDA/MAA approval, including Life Cycle Management (LCM)
  • A review of current European regulatory guidance for drug delivery devices and lessons from MDR implementation
  • Strengthening device optimisation with a review of article 117 and available EMA guidance
  • Future labelling requirements and next steps in regulatory guidance for injectable devices
  • 10:30 Morning Coffee

    11:00 Session Reserved for BSI Group

    11:40 Regulatory & engineering considerations and opportunities for next generation injectables made with high performance materials

    Caroline Prisk

    Caroline Prisk, Head of Regulatory Affairs, Victrex Plc

  • Market trends and opportunities impacting the design of autoinjector and wearable devices
  • A design engineers overview of the polymer material landscape
  • Update on regulatory considerations for selecting pharmaceutical-grade high performance polymers
  • Sustainability strategies when working with high performance PEEK polymers
  • 12:10 Networking Lunch

    13:10 Transforming formulation strategies for protein based injectable drug systems

    Vasco Filipe

    Vasco Filipe, Head Drug Product Development of Biologics, Sanofi
    View Bio

  • Enhancing drug formulation for large molecule drug delivery from a parenteral delivery perspective
  • Key considerations for large volume drug delivery: a review of high concentration stability
  • Elevating container options for injectable delivery protein-based
  • products with future directions and next steps required for progression of the field
  • 13:50 Maximising pharmaceutical development of novel injectable delivery technologies through sustainable approaches

    Cedric Gysel

    Cedric Gysel, Health Care Solutions Manager, Johnson & Johnson
    View Bio

  • An introduction to early phase primary packaging requirements of novel devices
  • Exploring drug formulation considerations for device optimisation and strategies to reduce wastage
  • Implementing end of life procedures for device disassembly and correct material disposal
  • 14:30 Addressing challenges Cell & gene therapy injectable delivery

    Annie Zavadil

    Annie Zavadil, Device Project Leader, Novartis

  • On overview of the cell and gene therapy injectable landscape
  • A review of current challenges in the administration of cell and gene therapy formulations
  • Exploring novel injectable device technologies as potential delivery options in cell and gene therapies
  • Discussing future development strategies for cell and gene therapy delivery
  • 15:10 Afternoon Tea

    15:40 The Importance of a Primary Container Selection Strategy in Combination Product Development

    Caroline  Zakrzewski

    Caroline Zakrzewski, Senior Engineer, AstraZeneca

     

  • Standardisation of primary container formats
  • Engagement of manufacturing and device development functions
  • Adaptation for novel presentations
  • Improved sustainability and cost saving
  • 16:20 Insights into novel primary container coatings for injectable devices

    Amber Witteman

    Amber Witteman, Founder - Managing Director, EPiWatch
    View Bio

  • Utilising a novel 2D coating formulation to extend shelf life of primary drug containers
  • Exploring current sustainability challenges for injectable devices and how to enhance sustainability in the future
  • Enhancing innovation for primary packaging of injectable drug delivery devices as a requirement for early-stage development
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 From regulator to regulated – working under combination product regulation

    Thomas Wejs Moeller

    Thomas Wejs Moeller, Director Global Regulatory Affairs - Device, Novo Nordisk
    View Bio

  • As former member of MDCG (authorities) and now heading Novo Nordisk RA devices Thomas will share his experience working with both sides of the EU combination product regulation.
  • Addressing topics like:
  • Challenges with art 117 in the MDR - Notifi ed Bodie Opinions 
  • EMA/NB - and approvals vs. opinions 
  • Where to be cognisant of gaps and how to move forward
  • 9:50 Global Regulatory Strategy for Combination Product Licensing

    Blake  Green

    Blake Green, Director Regulatory Affairs, Amgen Ltd
    View Bio

  • Exploring planning Input strategies for injectable devices
  • Global licensing application models
  • Shared vs country-specifi c documentation
  • Challenges to global harmonisation
  • 10:30 Morning Coffee

    11:00 Lessons in MDR regulatory compliance for injectable devices

    Jeanne Greathouse

    Jeanne Greathouse, Global Director Healthcare, BSI Group

  • Utilising post-market clinical follow up in reference to articles 86 and 87 to ensure device safety
  • Assessing clinical data usage, a review of relevant injectable devices
  • Next steps and considerations for MDR implementation in relation to injectable devices
  • 11:40 Considerations in pediatric injections

    Tiffany McIntire

    Tiffany McIntire, Principal Human Factors Engineer, Roche
    View Bio

  •  Aspects of use to consider
  • Relevant disease states
  • The Patient journey and the transition of responsibility
  •  Evolving ISO standard(s) and FDA expectations in human factors testing
  • 12:20 Networking Lunch

    13:20 Risk Management for Connected Delivery Devices

    Fatima Bennai-Sanfourche

    Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
    View Bio

  • Assessing the EU MDR requirements on device risk management process
  • Impact on usability engineering and human factors
  • Benefi t -risk assessment of drug-device combination products
  • 14:00 Panel Discussion: How to improve patient centricity of drug-device combination

  • How to reach a stage where the voices of both patients and researchers are equally represented during the drug development process
  • Discuss strategies to accelerate clinical development and trials, patient recruitment and retention through successful patient involvement
  • Addressing how the digital healthcare provides opportunities to address and to improve patient centricity.
  • Delving into global landscape changes.
  • Fatima Bennai-Sanfourche

    Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
    View Bio

    Jeanne Greathouse

    Jeanne Greathouse, Global Director Healthcare, BSI Group

    Tiffany McIntire

    Tiffany McIntire, Principal Human Factors Engineer, Roche
    View Bio

    Mark Milton-Edwards

    Mark Milton-Edwards, Head of Health Solutions, Teva UK Ltd
    View Bio

    Julia Frese

    Julia Frese, Director, TUV SUD Japan Ltd.
    View Bio

    14:40 Afternoon Tea

    15:10 Digital inhaler Case Study – and lessons from Aircraft Crashes!

    Mark Milton-Edwards

    Mark Milton-Edwards, Head of Health Solutions, Teva UK Ltd
    View Bio

  • Healthcare Lessons can be learnt from outside Healthcare
  • Real-World User Design and enduring needs must be clearly defi ned
  • Machine Learning & Prospective Research can be used to predict attacks
  • 15:50 Human Factors FDA collaborations

    Shannon Clark

    Shannon Clark, CEO, UserWise
    View Bio

  • A critical review of the U.S. FDA human factors protocols for injectable devices
  • Exploring sample size as a crucial component in human factors testing and lessons on when to modify it
  • Addressing frequent challenges in FDA human factors procedures and testing
  • Case Study related to Clinical Actual Use Testing of an Autoinjector
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Amber Witteman

    Amber Witteman

    Founder - Managing Director, EPiWatch
    Annie Zavadil

    Annie Zavadil

    Device Project Leader, Novartis
    Blake  Green

    Blake Green

    Director Regulatory Affairs, Amgen Ltd
    Caroline  Zakrzewski

    Caroline Zakrzewski

    Senior Engineer, AstraZeneca
    Caroline Prisk

    Caroline Prisk

    Head of Regulatory Affairs, Victrex Plc
    Cedric Gysel

    Cedric Gysel

    Health Care Solutions Manager, Johnson & Johnson
    Jeanne Greathouse

    Jeanne Greathouse

    Global Director Healthcare, BSI Group
    Julia Frese

    Julia Frese

    Director, TUV SUD Japan Ltd.
    Louise Place

    Louise Place

    Director, Devices Global CMC Regulatory Affairs, GSK
    Shannon Clark

    Shannon Clark

    CEO, UserWise
    Thomas Wejs Moeller

    Thomas Wejs Moeller

    Director Global Regulatory Affairs - Device, Novo Nordisk
    Tiffany McIntire

    Tiffany McIntire

    Principal Human Factors Engineer, Roche
    Vasco Filipe

    Vasco Filipe

    Head Drug Product Development of Biologics, Sanofi

    Amber Witteman

    Founder - Managing Director, EPiWatch
    Amber Witteman

    Amber Witteman is responsible for filling the EPIWatch’s strong IP’s containing a few novel techniques in the Med Tech industry, highlighted by Cortellius – Clarivate, ranked on number 1 out 10 and said to be “The Most Important Patents of The Med Tech Industry”. Amber is inventor of the NIP (Needle in Plunger, an ultra compact micro sized Pre-Filled Syringe Unit, with a focus on “Low Dept Space” and “Minimum Waist”- especially designed for replacement of syringes used in reusable Connected Drug Delivery Devices, The NIP is half the size of traditional syringes. Amber is also the inventor of a novel coating which extends the shelf life of PFS, vials, ampoules, cartridges, and other primary drug containers significantly, keeping the drugs, vaccines, etc. within the container cooled and protected from UV rays and Sunlight.

    Annie Zavadil

    Device Project Leader, Novartis
    Annie Zavadil

    Blake Green

    Director Regulatory Affairs, Amgen Ltd
    Blake  Green

    Blake Green is a Regulatory Affairs Senior Manager with Amgen’s Global Medical Devices Regulatory team. Based in Cambridge UK. Blake is a Devices Regulatory lead for medicinal product/medical device combination products and co-packaged medical devices in the biopharmaceutical sector. Prior to joining Amgen, Blake had significant international experience securing multi-national market clearance for manufacturers of medical devices, medical device/medicinal product combinations, medical software, personal protective equipment, and biocides, located throughout the United States of America, European Union, North Africa, Middle East, Far East, Turkey, Israel, Australia, Canada, and Peoples Republic of China.

    Caroline Zakrzewski

    Senior Engineer, AstraZeneca
    Caroline  Zakrzewski

    Caroline Prisk

    Head of Regulatory Affairs, Victrex Plc
    Caroline Prisk

    Cedric Gysel

    Health Care Solutions Manager, Johnson & Johnson
    Cedric Gysel

    Cedric Gysel is a Healthcare Solutions Manager for Johnson & Johnson Design, driving human-centered solutions for patients and customers and leading key innovation projects for device & packaging sustainability as we all product end of life programs across the pharmaceutical and medical device sectors of Johnson & Johnson. He has more than 15 years of experience with the development and design of devices and combination products. He holds a bachelor’s in pharmaceutical technology from the University of Basel and a master’s in medical device technology from the University of Applied Science.

    Fatima Bennai-Sanfourche

    Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
    Fatima Bennai-Sanfourche

    Dr. Fatima Bennai-Sanfourche is working currently as Senior Director of QA&RA Compliance for Medical Devices, Combinations Products, and eHealth at Bayer AG.
    Previously she worked in the medical affairs and Pharmacovigilance department at Bayer as Director, Medical Device Safety Global Pharmacovigilance/Medical device Safety officer.
    She has more than 15 years of experience in the quality management and Regulatory Affairs of medical devices field, and over 20 years of supervisory and leadership experience including hiring, training and performance evaluation.
    She studied Biology with a focus on Biochemistry, Immunology and Pharmacology, and did her PhD in Pharmacology and Pharmacochemistry in Strasbourg in France. She started her professional life with more university-oriented areas doing research and development in France, Sweden and Germany with a focus on cerebrovascular diseases, such as stroke, regulation of hypertension and development of immunoassays.
    In her current position by Bayer AG her focus is ensuring the regulatory compliance as well as high product quality of medical device, combination products and eHealth components of the Pharmaceuticals portfolio.
    She is also responsible for Ensuring compliant use of medical devices and medical software tools in the context of clinical investigations and clinical trials, incl. accordance with medical device Good Clinical Practice (GCP).
    She is also leading the project of the implementation of euMDR for PH-Bayer AG.
    She was nominated in 2019 by the European Commission as EFPIA observer for the PMSV (Post-Market Surveillance and Vigilance) subgroup (GROW.D4) responsible for the implementation of these process according the medical Device regulation. The period of nomination is of five years starting on 01 March 2019.
     

    Jeanne Greathouse

    Global Director Healthcare, BSI Group
    Jeanne Greathouse

    Julia Frese

    Director, TUV SUD Japan Ltd.
    Julia Frese

    By education biomedical engineer with a Master degree in business administration. Julia gained experience in development, regulatory approval of combination devices and ATMP products. She was further involved in the development of standards for ATMP products. Currently Julia Frese is heading the division of Medical and Health Services at TÜV SÜD Japan and is responsible for the development of article 117 service within the organisation. She is further co-chair of the Team NB working group for article 117.

    Louise Place

    Director, Devices Global CMC Regulatory Affairs, GSK
    Louise Place

    Originally training as a pharmaceutical scientist, Louise has over 14 years’ experience in drug delivery & medical devices with a focus on device technical management and regulatory strategy for EU & FDA submissions.
    Louise joined GSK in May 2020 and leads the Device team within CMC Regulatory with responsibility for global regulatory and advocacy strategy (Devices) across the GSK portfolio.
    With a solid background in inhalation and parenteral ‘combination products’ from concept to market through previous experience working at Pfizer, Oval Medical Technologies, and Cambridge Design Partnership, among others, Louise has a proven track record in supporting successful device submissions for different device types and markets.
     

    Mark Milton-Edwards

    Head of Health Solutions, Teva UK Ltd
    Mark Milton-Edwards

    Mark is responsible for the Product & Health Solutions within Digital Health at TEVA Pharmaceuticals. Over ten years with TEVA and prior to that sixteen with AstraZeneca. Mark has held various positions including R&D Project Leader, VP Sales & Marketing, Strategic Planning & Business Development, and Global Brand Lead. Graduated in Aeronautical Sciences and completed his MBA at Durham University, UK. During his career he has led technology & especially inhaler development teams through engineering, CMC characterisation, clinical evidence generation, registration within US, EU and International Markets and ultimately to successful global launch. Total Brand Leadership value >$2.5bn. Mark has numerous patents granted and pending in electronic communications, sports technologies, inhaled pharmaceutical development, and respiratory physiological function & predictive AI. Mark is the inventor of Digihaler®, the first FDA approved digital inhaler with built-in sensors.

    Shannon Clark

    CEO, UserWise
    Shannon Clark

    Shannon E. Clark is founder and CEO of UserWise, a consultancy that helps medical device manufacturers and start-ups to design safe and easy-to-use medical devices. The consultants at UserWise conduct usability testing for a variety of medical devices ranging from surgical robots to home-use injection platforms. UserWise consultants also perform safety assessments to comply with U.S. and international regulations related to Human Factors.

    Before founding UserWise in 2014, Shannon was a Human Factors Engineer at Intuitive Surgical and Abbott Laboratories.

    Shannon graduated from UCLA with a B.S. in Mechanical Engineering and a technical breadth in Technology Management. Shannon is additionally a Certified Professional Industrial Engineer, holds two patents, and has written and published three books.
     

    Thomas Wejs Moeller

    Director Global Regulatory Affairs - Device, Novo Nordisk
    Thomas Wejs Moeller

    Thomas is the Senior Director of Regulatory Affairs for Devices at Novo Nordisk and is responsible for devices and combination products.
    He has extensive experience with regulating medical devices in Denmark and Europe, and he comfortably balances between business aims and regulatory demands.
    As a former Director of Medical Devices in the Danish Medicines Agency and an MDCG member, he has worked with the public sector, MedTech-Industry and Patient-organisations to secure patient safety.
    Thomas has been elected Chair of the Competent Authorities for Medical Devices (CAMD). And has experience in national and international arenas—Europe with the EU commission, EMA, Notified Bodies, Authorities, and patient organisations.
    Thomas holds a master’s degree in political science from the University of Copenhagen. He has undertaken several courses and continuing education in project management and leadership and has several years of practical management experience.
     

    Tiffany McIntire

    Principal Human Factors Engineer, Roche
    Tiffany McIntire

    Tiffany has been in the pharmaceutical industry for almost 9 years developing medical devices end to end, primarily in the combination product space. She started her career at Lilly after finishing her studies in Psychology in 2014. While working at Lilly she obtained her masters in human-computer interaction. 5 years ago she jumped across the pond to work at Boehringer Ingelheim (BI). For the last 3.5 years she has been working as a Principal HF engineer for Roche in Basel.

    Vasco Filipe

    Head Drug Product Development of Biologics, Sanofi
    Vasco Filipe

    Vasco Filipe is a Biological Engineer and obtained a Ph.D. degree in Pharmaceutical Sciences from the Utrecht University (The Netherlands) in 2011. His thesis focused on the physicochemical characteristics, stability in biological fluids and immunogenicity of monoclonal antibody aggregates. After a post-doc in 2012 on a similar topic, he then joined Adocia in 2013 (Lyon, France), where he worked as the Project Leader for all monoclonal antibodies collaborations. In 2015 he joined Sanofi (Paris, France), where he now works as a Section Head of Formulation and Process Development in the department of Biologics Drug Product Development.

    Sponsors

    Exhibitors

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Attendee List

    Download

    Sponsors


    Victrex

    Sponsors
    http://www.victrex.com

    Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications which contain our sustainable materials – from smartphones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years’ experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, provide environmental and societal benefits, and drive value for our shareholders. Find out more at www.victrex.com

    Exhibitors


    PHC Group

    Exhibitors
    https://www.phchd.com/global/ivd

    The PHC Group provides products and services for diabetes management, life sciences and diagnostics, as well as enhanced healthcare solutions that are used by patients, healthcare professionals and researchers in over 125 countries. By integrating digital solutions with our expertise in precision technology that has been nurtured over decades, we provide the best-in-class devices and services for advancing basic research, diagnosis and medical treatment.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out